What is the recommended dose and infusion rate for intravenous immunoglobulin (IVIG) therapy?

IVIG Dosing and Administration

For primary immunodeficiency (PI), administer IVIG at 300-600 mg/kg every 3-4 weeks, starting at 0.01 mL/kg/min (0.5 mg/kg/min) and increasing to a maximum of 0.10 mL/kg/min (5 mg/kg/min) if tolerated. 1

Standard Dosing by Indication

Primary Immunodeficiency

• Dose: 300-600 mg/kg (6-12 mL/kg for 5% solution) every 3-4 weeks 1
• Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min)
• Maximum rate: 0.10 mL/kg/min (5 mg/kg/min) if tolerated after first 30 minutes 1
• Target: Adjust dose to achieve desired trough IgG levels (>6 g/L associated with reduced infections) 2

Immune Thrombocytopenic Purpura (ITP)

• Dose: 1 g/kg as a one-time dose, may repeat if necessary 3
• Alternative: 0.4 g/kg daily for 2-5 consecutive days 4, 5
• Use with corticosteroids when rapid platelet increase required 3

Guillain-Barré Syndrome

• Dose: 0.4 g/kg/day for 5 days (total 2 g/kg) 6
• Alternative: 2 g/kg IV over 5 days 6

Multisystem Inflammatory Syndrome in Children (MIS-C)

• Dose: 2 g/kg based on ideal body weight as single dose 7
• May divide into 1 g/kg daily over 2 days if cardiac dysfunction present 7
• Assess cardiac function and fluid status before administration 7

Pemphigus Vulgaris

• Dose: 2 g/kg divided over several days, repeated monthly 8
• Alternative: 1 g/kg may be used but 2 g/kg shows better dose-response 8

Infusion Rate Escalation Protocol

Start conservatively and escalate based on tolerance:

1. First 30 minutes: 0.01 mL/kg/min (0.5 mg/kg/min) 1
2. If tolerated: Gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) 1
3. For 10% solutions: Can safely escalate to 0.14 mL/kg/min in most patients, reducing infusion time 9
4. Individual titration: Some patients tolerate rates up to 8.0 mL/kg/h after gradual escalation 10

Monitor vital signs throughout infusion. Slow or stop if adverse reactions occur; may resume at lower rate once symptoms resolve. 1

High-Risk Patient Modifications

Renal Dysfunction or Thrombosis Risk

• Administer at minimum dose and infusion rate practicable 1
• Ensure adequate hydration before administration 1
• Monitor blood viscosity in hyperviscosity risk 1
• Discontinue if renal function deteriorates 1

Cardiac Dysfunction

• Assess cardiac function and fluid status before infusion 7
• Consider divided dosing (1 g/kg daily over 2 days instead of single 2 g/kg dose) 7
• May require diuretics with administration 7

First-Time or Restarted Patients (>8 weeks gap)

• Higher risk for fever, chills, nausea, vomiting 1
• Start at slowest rate with close monitoring 5
• Risk of complement-mediated reactions in immunodeficient patients 5

Critical Administration Details

Do not:

• Dilute with IV fluids 1
• Mix with other medications 1
• Use different IVIG formulations together 1
• Use frozen or turbid solutions 1
• Save partially used vials (no preservative) 1

Infuse through separate IV line only 1

Common Pitfalls

1. Inadequate dosing in obese patients: Body-weight-adjusted dosing needed to achieve therapeutic IgG levels and reduce infection risk 2

2. Treatment interruptions: Cause IgG level drops and symptom deterioration; maintain consistent dosing intervals 11

3. Infrequent dosing intervals: More frequent dosing (Q2-3W vs Q4W) provides more stable IgG levels and may prevent periodic symptom worsening 11

4. IgA deficiency concerns: Very rare anaphylaxis risk; IgA deficiency alone is NOT a contraindication to IVIG 12

5. Second IVIG dose in refractory cases: NOT recommended due to volume overload and hemolytic anemia risk 7

Monitoring Requirements

• Vital signs: Throughout infusion 1
• IgG trough levels: Target >6 g/L associated with reduced infections 2
• Renal function: BUN, creatinine, urine output in at-risk patients 12
• Hemolysis: Especially after high-dose infusions 12
• Liver enzymes: Baseline and periodic monitoring 12